Orion Oyj (OTCMKTS:ORINY) Reaches New 1-Year Low at $17.50

Shares of Orion Oyj (OTCMKTS:ORINY) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $17.50 and last traded at $17.50, with a volume of 78 shares traded. The stock had previously closed at $17.50.

Orion Oyj Price Performance

The company has a market cap of $4.94 billion, a P/E ratio of 20.83 and a beta of 0.23. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.10 and a quick ratio of 1.59. The company has a 50 day moving average of $18.54 and a 200-day moving average of $20.14.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.29 earnings per share for the quarter. The company had revenue of $345.76 million for the quarter. Orion Oyj had a net margin of 17.74% and a return on equity of 26.81%. On average, equities analysts predict that Orion Oyj will post 0.89 earnings per share for the current year.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.